Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: an in vivo study.

PubWeight™: 0.76‹?›

🔗 View Article (PMC 2777119)

Published in Thromb J on November 10, 2009

Authors

Ramin Artang1, Niels J Frandsen, Jørn Dalsgaard Nielsen

Author Affiliations

1: Coagulation Laboratory, Gentofte University Hospital, Hellerup, Denmark. ramin_artang@yahoo.com.

Articles cited by this

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med (1997) 6.19

Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) Circulation (1997) 2.90

Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet (1996) 2.75

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 2.59

Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet (1999) 1.70

Comparison of thrombelastography with common coagulation tests. Thromb Haemost (1981) 1.58

Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathies. J Clin Monit (1987) 1.12

The thromboelastography and the thromboelastograph technique. Semin Thromb Hemost (1995) 1.02

Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. Anesth Analg (2000) 0.91

Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J Clin Pathol (2000) 0.87

Thrombelastography in healthy volunteers, patients with stable angina and acute chest pain. Thromb Res (2000) 0.85

High-dose tinzaparin in pregnancy and the need for urgent delivery. Br J Anaesth (2002) 0.83

Role of thromboelastography in evaluating other anticoagulant agents: warfarin and heparin-dihydroergotamine. Semin Thromb Hemost (1995) 0.83

Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients. Thromb Res (2006) 0.81

Thrombelastography after aspirin ingestion in pregnant and non-pregnant subjects. Br J Anaesth (1992) 0.80

Thromboelastography for the assessment of hypercoagulability during general surgery. Semin Thromb Hemost (1995) 0.80

Usefulness of thrombelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis. Artif Organs (1990) 0.78

Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparins in cardiovascular medicine. Am Heart J (2000) 0.78

Thromboelastographic modifications induced by intravenous and subcutaneous heparin administration. Semin Thromb Hemost (1995) 0.78

Articles by these authors

Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol (2013) 2.19

Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J (2011) 1.54

Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) - a review of a new treatment paradigm. Biologics (2012) 0.96

[Effect of Coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger (2003) 0.79

[Resuscitation with automated external defibrillators outside hospital]. Ugeskr Laeger (2005) 0.78

Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. Semin Thromb Hemost (2009) 0.77

Inadequate use of prophylaxis against venous thromboembolism in Danish medical departments. Dan Med Bull (2011) 0.75

[Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis]. Ugeskr Laeger (2004) 0.75

[Thrombelastography--should it be done and when?]. Ugeskr Laeger (2006) 0.75

[Increased bleeding tendency induced by beta-lactam antibiotics]. Ugeskr Laeger (2005) 0.75

[The use of venous thromboprophylaxis in Danish medical departments. A questionnaire survey]. Ugeskr Laeger (2005) 0.75

[Diagnostic strategy in patients with clinically suspected deep vein thrombosis]. Ugeskr Laeger (2008) 0.75

Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease. J Clin Epidemiol (2012) 0.75